Estradiol-responsive mouse genes overlap with human lipid and coronary artery disease signals, implying translational relevance to human metabolic risk, with XY-specific changes also linking to BMI in men and potential male-focused metabolic effects.

The study investigates whether estradiol’s liver-protective effects differ by sex or follow a shared, sex-concordant program across hepatocyte subtypes and liver zones, including pericentral and periportal regions.

Researchers attribute sex-specific differences to a mix of hormones, fat distribution, and immune activity, pointing toward potential sex-differentiated therapies.

The research reframes estrogen therapy for metabolic disease as a sex-informed, zonation-aware regulation with both shared protective actions and sex-specific remodeling, guiding dosing and patient selection to maximize benefit and minimize risk.

Obesity impacts men and women differently, underscoring the need for personalized medical approaches while reaffirming obesity as a significant risk for all.

A single-nucleus RNA sequencing study maps how chronic estradiol treatment reshapes gene activity across liver cell types in obese, gonadectomized mice, separating hormonal effects from endogenous hormones.

Technically, single-nucleus RNA sequencing provides high-resolution, cell-type-specific liver transcriptomics, offering an open-access resource linking estradiol signaling to human metabolic disease genetics.

Findings warrant testing in larger populations to determine how sex differences translate into clinical risk and to guide targeted treatments.

Future questions include whether sex-specific transcriptional changes lead to different physiological outcomes, which regulators are causal, and how age, diet, or gonadal status modulate these programs.

Sex-specific effects sit atop shared responses: XY mice show additional suppression of lipid/energy pathways in pericentral hepatocytes and reduced oxidative phosphorylation in periportal hepatocytes, while XX mice show unique regulation of glucose and lipid utilization, suggesting sex chromosome complement as an intrinsic modifier.

Network analyses reveal a shared estrogen receptor–related regulatory backbone, with sex-specific transcriptional drivers and greater intercellular signaling changes in XY livers under estradiol treatment.

Global context: metabolic syndrome affected about 1.5 billion adults in 2023, highlighting the broad health burden of obesity and related conditions.